Bone Biologics Corp Warrants

NASDAQ
BBLGW
Stock
Yield per half year: -27.34%
Dividend yield: 0%

Share chart Bone Biologics Corp Warrants

About Bone Biologics Corp Warrants

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.

more details
The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Grade

Underestimation
Title Value Grade
P/S 0 0
P/BV 17.42 1
P/E 0 0
EV/EBITDA -13.95 0
Total: 2.13
Efficiency
Title Value Grade
ROA, % -108.23 0
ROE, % -128.71 0
Total: 0
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA 0 10
Total: 9.8
Growth impulse
Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 398.47 10
Yield EPS, % 1903.3 10
Total: 8

Company management

Head Job title Payment Year of birth
Mr. Jeffrey Frelick CEO & President 1966 (59 years)
Ms. Deina H. Walsh Chief Financial Officer 1964 (61 year)

About company

Address: United States, Burlington, 2 Burlington Woods Drive - Open in google maps, Open in yandex maps
Website: https://www.bonebiologics.com